These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9174199)

  • 1. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Rybak MJ; Houlihan HH; Mercier RC; Kaatz GW
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1359-63. PubMed ID: 9174199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Houlihan HH; Mercier RC; Rybak MJ
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2497-501. PubMed ID: 9371356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.
    Kang SL; Rybak MJ
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1505-11. PubMed ID: 7492094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
    Entenza JM; Drugeon H; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.
    Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):701-5. PubMed ID: 8851596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.
    Lee DG; Chun HS; Yim DS; Choi SM; Choi JH; Yoo JH; Shin WS; Kang MW
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3768-73. PubMed ID: 14638480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection.
    Lewis RE; Klepser ME; Ernst EJ; Lund BC; Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2005-9. PubMed ID: 10428927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.
    Fantin B; Leclercq R; Merlé Y; Saint-Julien L; Veyrat C; Duval J; Carbon C
    Antimicrob Agents Chemother; 1995 Feb; 39(2):400-5. PubMed ID: 7726505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis.
    Berthaud N; Huet Y; Diallo N; Desnottes JF
    J Antimicrob Chemother; 1997 May; 39 Suppl A():93-8. PubMed ID: 9511071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic interaction between RP 59500 and gram-positive bacteria infecting fibrin clots.
    Turcotte A; Bergeron MG
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2211-5. PubMed ID: 1444302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of quinupristin/dalfopristin and seven other antimicrobials against methicillin-susceptible and methicillin-resistant nosocomial Staphylococcus aureus bloodstream isolates.
    Nikolaidis P; Metallidis S; Katikaridou E; Chatzidimitriou M; Kollaras P; Tsona A; Koumentaki E; Tourkantonis A
    J Chemother; 2002 Dec; 14(6):544-6. PubMed ID: 12583543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.
    Low DE; Nadler HL
    J Antimicrob Chemother; 1997 May; 39 Suppl A():53-8. PubMed ID: 9511063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
    Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
    Aeschlimann JR; Zervos MJ; Rybak MJ
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Huang V; Rybak MJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):302-8. PubMed ID: 15616309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.
    Vouillamoz J; Entenza JM; Féger C; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1789-95. PubMed ID: 10858332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.